Intracerebral Hemorrhage

Strokes were reported to be a rare adverse event following the administration of a COVID-19 vaccine, according to a study in Neurology.

In patients with acute ischemic stroke with large vessel occlusion who underwent endovascular therapy, tirofiban did not improve outcomes and raised risk for intracerebral hemorrhage, researchers reported.

Anger or emotional upset was associated with all stroke types, according to study findings published in European Heart Journal.

Men and women with ischemic stroke had improved functional outcomes in the past 2 decades, likely due in part to the development of acute reperfusion therapy, according to results of a prospective, registry cohort study.

Antithrombotic use after a transient focal neurological episode, as well as motor forms of these episodes, increased risk for lobar intracerebral hemorrhage, according to results of a systematic review and meta-analysis.

Women were found to be underrepresented in clinical trials looking at stroke when compared to the prevalence of stroke among women in the disease population, according to study results published in Neurology.

Restarting antiplatelet therapy did not significantly increase the risk for recurrent intracerebral hemorrhage or major vascular events, according to a study in JAMA Neurology.

Annual strokes and related deaths increased significantly between 1990 and 2019, despite significant reductions in age-standardized rates, according to a systematic analysis published in The Lancet Neurology.

Intracerebral hemorrhage disproportionately affected and occurred earlier in uninsured Black and Hispanic people with untreated hypertension, according to study data published in JAMA Network Open.

Results from an analytical decision model demonstrated that short-term, 7-day prophylaxis “dominates” long-term therapy for seizure prophylaxis after spontaneous intracerebral hemorrhage.